VIZIMPRO, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
